Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: A randomized long drug-eluting stent v trial

Circulation: Cardiovascular Interventions

Volumn 7, Issue 3, 2014, Pages 322-329

  Lee, Jong Young ^a   Park, Duk Woo ^a   Kim, Young Hak ^a   Ahn, Jung Min ^a   Kim, Won Jang ^a   Kang, Soo Jin ^a   Lee, Seung Whan ^a   Lee, Cheol Whan ^a   Park, Seong Wook ^a   Yun, Sung Cheol ^a   Yang, Tae Hyun ^b   Lee, Bong Ki ^c   Lee, Nae Hee ^d   Yang, Joo Young ^e   Shin, Won Yong ^d   Park, Hun Sik ^f   Kim, Kee Sik ^g   Hur, Seung Ho ^h   Lee, Sung Yun ⁱ   Park, Jong Seon ^j   Choi, Yun Seok ^k   Lee, Seung Uk ^l   Her, Sung Ho ^m   Park, Seung Jung ^a   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

^d Soonchunhyang University   (South Korea)

^e National Health Insurance Corporation   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

^g Catholic University of Daegu   (South Korea)

^h Dongsan Medical Center   (South Korea)

ⁱ Inje University   (South Korea)

^j Yeungnam University Hospital   (South Korea)

^k The Catholic University of Korea   (South Korea)

^l Gwangju Christian Hospital   (South Korea)

^m Daejeon St Mary's Hospital   (South Korea)

more..

Author keywords

Angioplasty; Biolimus; Coronary artery disease; Everolimus; Stents

Indexed keywords

EVEROLIMUS; RAPAMYCIN; UMIROLIMUS;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84905816188     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.000841     Document Type: Article

References (25)

1. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents. Circulation. 2006;113:2293-2300.
2. Suh J, Park DW, Lee JY, Jung IH, Lee SW, Kim YH, Lee CW, Cheong SS, Kim JJ, Park SW, Park SJ. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv. 2010;3:383-389.
3. Ahn JM, Park DW, Kim YH, Song H, Cho YR, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Han S, Lee SY, Lee BK, Cho JH, Yang TH, Lee NH, Yang JY, Park JS, Shin WY, Kim MH, Bae JH, Kim MK, Yoon J, Park SJ. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. Circ Cardiovasc Interv. 2012;5:633-640.
4. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee J Y, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee SW, Lee SW, Lee K, Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ. Comparison of everolimus-and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv. 2011;4:1096-1103.
5. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW. Randomized comparison of the nobori biolimus a9-eluting coronary stent with the taxus liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The nobori 1 trial-phase 2. Circ Cardiovasc Interv. 2009;2:188-195.
6. Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, Kaltoft A, Maeng M, Kristensen SD, Bøtker HE, Terkelsen CJ, Villadsen AB, Ravkilde J, Aarøe J, Madsen M, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V Investigators. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet. 2013;381:661-669.
7. Meredith IT, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW, Teirstein PS, Starzyk RM, Allocco DJ, Dawkins KD. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and in-travascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention. 2011;7:84-90.
8. Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651-660.
9. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700-1708.
10. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:2574-2609.
11. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJ. Comparison of zo-tarolimus-eluting stents with sirolimus-and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the effcacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol. 2010;56:1187-1195.
12. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-elut-ing stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation. 2007;115:2352-2357.
13. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, Stone GW, Waksman R, Leon MB. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol. 2002;39:274-280.
14. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classifcation and implications for long-term outcome. Circulation. 1999;100:1872-1878.
15. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ; Long-DES-II Study Investigators. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006;114:2148-2153.
16. Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and effcacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention. 2005;1:53-57.
17. Chow SC, Liu JP. Design and Analysis of Clinical Trials. 2nd ed. New York, NY: John Wiley and Son; 2004.
18. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
19. Romagnoli E, Godino C, Ielasi A, Gasparini G, Tzifos V, Sciahbasi A, Lioy E, Presbitero P, Colombo A, Sangiorgi G. Resolute Italian study in all comers: immediate and one-year outcomes. Catheter Cardiovasc Interv. 2012;79:567-574.
20. Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, Nanto S, Fujii K, Inoue N, Namiki A, Kimura T, Mitsudo K. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-elut-ing stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv. 2012;80:789-796.
21. Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, Antonic Z, Miloradovic V, Topic D, Paunovic D. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention. 2008;3:574-579.
22. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-elut-ing stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-1948.
23. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT frst trial. EuroIntervention. 2005;1:58-65.
24. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286-294.
25. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913.